Menu

CRISPR Corrects Sickle Cell-Causing Gene in Human Cells

Once implanted in mice, the edited stem cells produced normal hemoglobin.

Oct 13, 2016
Kerry Grens

WIKIMEDIA, DIANA GRIBScientists have used the CRISPR-Cas9 gene-editing technique to rewrite the genetic mutation in blood cells that causes sickle cell disease. Once these treated hematopoietic progenitors, which had been harvested from patients, were given to mice, the cells began to produce healthy hemoglobin.

“What we have right now, if we can scale it up and make sure it works well, is already enough to form the basis of a clinical trial to cure sickle cell disease with gene editing,” study coauthor Mark DeWitt, a postdoctoral fellow at the University of California, Berkeley, told The Los Angeles Times. His team published its results yesterday (October 12) in Science Translational Medicine.

As STAT News pointed out, the technique is not 100 percent efficient. Only a fraction of the treated cells successfully ended up with the right edits; and only 2 percent to 6 percent of the corrected cells retained the edits after 16 weeks once administered to the mice. “A few percent might seem low, said Jacob Corn, scientific director of the [UC Berkeley] Innovative Genomics Initiative and a co-leader of the study, but studies suggest that having just 2 percent to 5 percent of healthy red blood cells could be enough to cure sickle cell,” STAT reported.

Stuart Orkin, a blood stem cell biologist at Harvard Medical School who was not involved in the work, told Chemical & Engineering News that CRISPR is just one route to repair the gene that causes sickle cell anemia. “There is heightened interest given the hoopla around CRISPR/Cas9 but there are other ways to edit,” Orkin said. “Ultimately, the approach that achieves excellent patient outcomes without side-effects is what is desired and there may be several different ways to achieve this end.”

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.